NATR · Natures Sunshine Products Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $122.89M | - | $128.34M | $114.75M | $113.25M | - | $114.61M | $110.55M | $110.99M | - |
| Cost of Revenue | $32.91M | - | $34.29M | $32.45M | $31.65M | - | $32.86M | $31.66M | $32.02M | - |
| Gross Profit | $89.98M | - | $94.05M | $82.30M | $81.60M | - | $81.76M | $78.89M | $78.98M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $43.54M | - | $45.73M | $43.66M | $40.58M | - | $40.95M | $38.56M | $40.78M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $3.22M | - | - | - | $3.50M | - | - | - | $3.16M | - |
| Operating Income | $9.54M | - | $8.97M | $4.27M | $6.17M | - | $5.28M | $5.64M | $4.62M | - |
| Interest Expense | $35.0K | - | $26.0K | $24.0K | $12.0K | - | - | - | - | - |
| Income Tax | $3.04M | - | $4.14M | $2.02M | $2.23M | - | $3.25M | $2.94M | $2.17M | - |
| Net Income | $5.12M | - | $5.33M | $5.33M | $4.75M | - | $4.35M | $1.35M | $2.32M | - |
| EPS - Basic | $0.29 | - | $0.30 | $0.29 | $0.26 | - | $0.23 | $0.07 | $0.12 | - |
| EPS - Diluted | $0.29 | - | $0.30 | $0.28 | $0.25 | - | $0.23 | $0.07 | $0.12 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $87.58M | $93.89M | $95.55M | $81.34M | $86.49M | $84.70M | $78.70M | $68.69M | $77.77M | $82.37M |
| Accounts Receivable | $12.55M | $8.60M | $15.11M | $13.03M | $11.41M | $9.48M | $11.40M | $11.29M | $9.69M | $8.83M |
| Inventory | $67.13M | $68.31M | $67.33M | $69.32M | $64.93M | $59.44M | $62.30M | $62.30M | $62.65M | $66.89M |
| Accounts Payable | $8.25M | $8.02M | $7.12M | $9.92M | $9.87M | $8.91M | $8.88M | $8.42M | $9.03M | $7.91M |
| Current Assets | $178.59M | $178.84M | $186.08M | $171.84M | $170.78M | $160.58M | $163.53M | $152.04M | $160.16M | $165.82M |
| Total Assets | $261.46M | $261.15M | $264.81M | $254.88M | $252.70M | $240.85M | $245.33M | $235.83M | $247.27M | $249.77M |
| Current Liabilities | $71.37M | $78.54M | $83.65M | $75.85M | $70.74M | $65.69M | $67.15M | $63.65M | $68.88M | $76.75M |
| Long-term Debt | - | - | - | - | - | - | - | - | $2.11M | - |
| Total Liabilities | $94.54M | $99.59M | $98.10M | $91.19M | $85.60M | $79.86M | $82.72M | $79.43M | $87.56M | $90.23M |
| Stockholders' Equity | $166.92M | $161.55M | $166.70M | $163.68M | $167.10M | $160.99M | $162.62M | $156.40M | $159.71M | $159.54M |
| Retained Earnings | $82.05M | $76.93M | $72.82M | $67.49M | $62.15M | $57.41M | $57.73M | $53.38M | $52.03M | $49.71M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.85M) | - | - | - | $2.61M | - | - | - | $2.19M | - |
| Investing Cash Flow | ($2.48M) | - | - | - | ($1.11M) | - | - | - | ($3.69M) | - |
| Financing Cash Flow | ($1.58M) | - | - | - | ($731.0K) | - | - | - | $107.0K | - |
| CapEx | $2.48M | - | - | - | $1.11M | - | - | - | $3.69M | - |
| Free Cash Flow | ($4.33M) | - | - | - | $1.50M | - | - | - | ($1.50M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 73.2% | - | 73.3% | 71.7% | 72.1% | - | 71.3% | 71.4% | 71.2% | - |
| Operating margin | 7.8% | - | 7.0% | 3.7% | 5.4% | - | 4.6% | 5.1% | 4.2% | - |
| EBITDA margin | 10.4% | - | - | - | 8.5% | - | - | - | 7.0% | - |
| Net margin | 4.2% | - | 4.2% | 4.6% | 4.2% | - | 3.8% | 1.2% | 2.1% | - |
| Free cash flow margin | -3.5% | - | - | - | 1.3% | - | - | - | -1.4% | - |
| FCF / Net income | -0.85 | - | - | - | 0.32 | - | - | - | -0.65 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 35.4% | - | 35.6% | 38.1% | 35.8% | - | 35.7% | 34.9% | 36.7% | - |
| Effective tax rate | 37.2% | - | 43.7% | 27.5% | 31.9% | - | 42.8% | 68.5% | 48.3% | - |
| Return on assets | 2.0% | - | 2.0% | 2.1% | 1.9% | - | 1.8% | 0.6% | 0.9% | - |
| Return on equity | 3.1% | - | 3.2% | 3.3% | 2.8% | - | 2.7% | 0.9% | 1.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | 1.5% | - |
| Liquidity | ||||||||||
| Current ratio | 2.50 | 2.28 | 2.22 | 2.27 | 2.41 | 2.44 | 2.44 | 2.39 | 2.33 | 2.16 |
| Quick ratio | 1.56 | 1.41 | 1.42 | 1.35 | 1.50 | 1.54 | 1.51 | 1.41 | 1.42 | 1.29 |
| Cash ratio | 1.23 | 1.20 | 1.14 | 1.07 | 1.22 | 1.29 | 1.17 | 1.08 | 1.13 | 1.07 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | 0.01 | - |
| Debt / Assets | - | - | - | - | - | - | - | - | 0.01 | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 0.27 | - |
| Interest coverage | 272.7x | - | 345.2x | 178.1x | 514.3x | - | - | - | - | - |
| Equity multiplier | 1.57 | 1.62 | 1.59 | 1.56 | 1.51 | 1.50 | 1.51 | 1.51 | 1.55 | 1.57 |
| Liabilities / Assets | 0.36 | 0.38 | 0.37 | 0.36 | 0.34 | 0.33 | 0.34 | 0.34 | 0.35 | 0.36 |
| Efficiency | ||||||||||
| Asset turnover | 0.47 | - | 0.48 | 0.45 | 0.45 | - | 0.47 | 0.47 | 0.45 | - |
| Inventory turnover | 0.49 | - | 0.51 | 0.47 | 0.49 | - | 0.53 | 0.51 | 0.51 | - |
| Days sales outstanding | 37d | - | 43d | 41d | 37d | - | 36d | 37d | 32d | - |
| Days inventory outstanding | 744d | - | 717d | 780d | 749d | - | 692d | 718d | 714d | - |
| Days payable outstanding | 91d | - | 76d | 112d | 114d | - | 99d | 97d | 103d | - |
| Cash conversion cycle | 690d | - | 684d | 710d | 672d | - | 630d | 658d | 643d | - |
| Valuation | ||||||||||
| P / E | 82.7x | - | 51.7x | 52.8x | 50.2x | - | 59.2x | 215.3x | 173.1x | - |
| P / B | 2.6x | - | 1.7x | 1.7x | 1.4x | - | 1.6x | 1.8x | 2.5x | - |
| P / S | 3.5x | - | 2.2x | 2.4x | 2.1x | - | 2.2x | 2.6x | 3.6x | - |
| EV / EBITDA | 26.8x | - | - | - | 15.5x | - | - | - | 41.6x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 8.5% | - | 12.0% | 3.8% | 2.0% | - | 3.1% | -5.1% | 2.2% | - |
| Revenue CAGR (3y) | 4.2% | - | 7.1% | 3.3% | 0.8% | - | -0.0% | 0.5% | 2.7% | - |
| Revenue CAGR (5y) | 3.7% | - | 5.1% | 5.6% | 3.4% | - | 5.3% | 4.0% | 4.0% | - |
| Gross profit growth (YoY) | 10.3% | - | 15.0% | 4.3% | 3.3% | - | 0.6% | -6.8% | 2.6% | - |
| Operating income growth (YoY) | 54.7% | - | 69.9% | -24.2% | 33.5% | - | -9.4% | -19.9% | 2588.4% | - |
| Net income growth (YoY) | 7.8% | - | 22.7% | 295.3% | 104.5% | - | 53.5% | -44.3% | 169.9% | - |
| EPS growth (YoY) | 16.0% | - | 30.4% | 300.0% | 108.3% | - | 53.3% | -41.7% | 200.0% | - |
| EPS CAGR (3y) | 93.5% | - | - | 110.5% | - | - | -1.4% | -39.7% | -15.7% | - |
| EPS CAGR (5y) | 7.7% | - | -2.5% | -0.7% | 10.8% | - | 26.9% | -12.9% | 5.9% | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | -34.4% | - | - | - | - | - |
| Book value growth (YoY) | -0.1% | 0.3% | 2.5% | 4.7% | 4.6% | 0.9% | 7.0% | 4.7% | 8.9% | 8.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$480.14M totalAsia Segment$221.78M · 46.2%
North America Segment$143.61M · 29.9%
Europe Segment$93.13M · 19.4%
Latin America And Other Segment$21.62M · 4.5%
Product / service
$224.28M totalGeneral Health Products$83.63M · 37.3%
Cardiovascular Products$54.55M · 24.3%
Digestive Products$47.67M · 21.3%
Immunity Products$14.44M · 6.4%
Weight Management Products$11.40M · 5.1%
Personal Care Products$10.07M · 4.5%
Shipping And Handling$2.50M · 1.1%
Geographic
$480.14M totalOther Countries$172.56M · 35.9%
US$133.39M · 27.8%
TW$67.28M · 14.0%
JP$56.07M · 11.7%
KR$50.84M · 10.6%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing NATURES SUNSHINE PRODUCTS INC against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Mar 26, 2021 | $1.0000 |
| Mar 20, 2017 | $0.1000 |
| Nov 21, 2016 | $0.1000 |
| Aug 19, 2016 | $0.1000 |
| May 23, 2016 | $0.1000 |
| Mar 9, 2016 | $0.1000 |
| Nov 16, 2015 | $0.1000 |
| Aug 21, 2015 | $0.1000 |
| May 20, 2015 | $0.1000 |
| Mar 10, 2015 | $0.1000 |
| Nov 18, 2014 | $0.1000 |
| Sep 4, 2014 | $1.5000 |
| Aug 14, 2014 | $0.1000 |
| May 19, 2014 | $0.1000 |
| Mar 26, 2014 | $0.1000 |
| Mar 19, 2014 | $0.1000 |
| Nov 14, 2013 | $0.1000 |
| Aug 15, 2013 | $1.6000 |
| May 16, 2013 | $0.1000 |
| Mar 14, 2013 | $0.1000 |
| Nov 13, 2012 | $0.0500 |
| Aug 9, 2012 | $0.0500 |
| May 16, 2012 | $0.0500 |